Mendus has announced an updated clinical development strategy for vididentel in myeloid malignancies. The company continues to report positive long-term data from the phase IIa ADVANCE II study, where 13 of 20 AML patients are still alive after a median follow-up of 48 months. Vididentel will now be developed for all AML risk groups after remission as well as for chronic myeloid leukemia (CML). Mendus is reducing its staff from 28 to 19 people to finance the new clinical studies.
|
Published October 2, 2025
Mendus updates clinical strategy for vididencel
Notes
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account